united therapeutics glp-1 receptor agonist A schematic overview of agonists: classification, drug “Weighing In” on GLP-1 Receptor

The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodiumglucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM

Obesity (Silver Spring) 2015;23:20752082

For NPs, these broad effects highlight the importance of aligning drug selection with individual patient profiles while monitoring metabolic response and overall health outcomes

Injections, drops, or lozenges

doi: 10.1016/S0140-6736(09)61375-1 11 AthaudaD.FoltynieT

LDN, Nordhorn, Germany)